Madrigal PharmaceuticalsMDGL
MDGL
About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Employees: 528
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
128% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 32
111% more call options, than puts
Call options by funds: $346M | Put options by funds: $164M
20% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 12 (+2) [Q1 2025]
18% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 91
13% more funds holding
Funds holding: 281 [Q4 2024] → 317 (+36) [Q1 2025]
10% more capital invested
Capital invested by funds: $7.08B [Q4 2024] → $7.81B (+$731M) [Q1 2025]
1.72% more ownership
Funds ownership: 105.23% [Q4 2024] → 106.95% (+1.72%) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$420
42%
upside
Avg. target
$445
51%
upside
High target
$460
56%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
UBS Eliana Merle | 55%upside $458 | Buy Maintained | 2 May 2025 |
B. Riley Securities Mayank Mamtani | 56%upside $460 | Buy Reiterated | 2 May 2025 |
Canaccord Genuity Edward Nash | 42%upside $420 | Buy Maintained | 2 May 2025 |
JMP Securities Jonathan Wolleben | 50%upside $443 | Market Outperform Reiterated | 24 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT.
Positive
Seeking Alpha
4 weeks ago
In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals
Madrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include potential approval of Rezdiffra in Europe, Q2 '25 earnings and business development, with MDGL indicating they are keen to add to their pipeline. Results from the MAESTRO-NASH OUTCOMES trial are not expected until 2027, but recent data from MAESTRO-NAFLD-1 provide some hint of the potential efficacy of Rezdiffra in some patients with cirrhosis.
Positive
The Motley Fool
1 month ago
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds of companies vying for investors' attention, separating the wheat from the chaff can be challenging.
Neutral
GlobeNewsWire
1 month ago
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra. Patients (n=122) in the study achieved significant improvements from baseline in liver stiffness, liver fat, fibrosis biomarkers, liver volume and risk scores for clinically significant portal hypertension (CSPH).
Positive
Seeking Alpha
1 month ago
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Madrigal Pharmaceuticals has a first-mover advantage in the huge MASH market due to the approval of Rezdiffra just over a year ago. The initial rollout of the compound is encouraging, and the company is expecting a huge surge in revenues in FY2025. Most analyst firms are positive around the company's prospects, and Madrigal has some potential additional catalysts on the horizon.
Neutral
Seeking Alpha
1 month ago
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive Officer and Director Mardi Dier - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Andrea Newkirk - Goldman Sachs Ritu Baral - TD Cowen Akash Tewari - Jefferies Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Good day, and thank you for standing by.
Positive
Zacks Investment Research
1 month ago
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Negative
Zacks Investment Research
1 month ago
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports first-quarter 2025 financial results and provides corporate updates.
Neutral
GlobeNewsWire
1 month ago
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands.
Charts implemented using Lightweight Charts™